Novavax and Rovi end vaccine agreement
This article was originally published in Scrip
Executive Summary
Novavax has ended negotiations with Rovi Pharmaceuticals in pursuit of a collaboration to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in Spain. The split was blamed on the two companies' "inability to agree on acceptable terms of the proposed collaboration and to obtain the necessary funding commitments for the programme".